K Brust1, A Evans2, R Plemmons3. 1. Division of Infectious Disease, Scott & White Healthcare, Texas A&M Health Science Center College of Medicine, Temple, TX, USA kbrust@sw.org. 2. Department of Pharmacy, Scott & White Healthcare, Temple, TX, USA. 3. Division of Infectious Disease, Scott & White Healthcare, Texas A&M Health Science Center College of Medicine, Temple, TX, USA.
Abstract
OBJECTIVES: To review cases of multidrug-resistant (MDR) Gram-negative bacillus urinary tract infections (UTIs) treated with tigecycline and the literature related to this subject. METHODS: We performed a systematic review of the literature identifying patients with MDR Gram-negative bacillus UTIs treated with tigecycline. RESULTS: Fourteen cases describing treatment of UTIs caused by MDR Gram-negative bacilli with tigecycline are reviewed. Favourable clinical outcomes were noted in 11 of 14 cases. An initial favourable microbiological outcome was noted in 12 cases. Post-treatment cultures in two cases were positive for tigecycline-resistant organisms. CONCLUSIONS: The clinical efficacy of tigecycline for treatment of UTIs has not been extensively evaluated. Based on the available literature, tigecycline appears to have efficacy in some patients with MDR Gram-negative bacillus UTIs. Further research in this area is needed to fully elucidate the role of tigecycline in treating such patients.
OBJECTIVES: To review cases of multidrug-resistant (MDR) Gram-negative bacillus urinary tract infections (UTIs) treated with tigecycline and the literature related to this subject. METHODS: We performed a systematic review of the literature identifying patients with MDR Gram-negative bacillus UTIs treated with tigecycline. RESULTS: Fourteen cases describing treatment of UTIs caused by MDR Gram-negative bacilli with tigecycline are reviewed. Favourable clinical outcomes were noted in 11 of 14 cases. An initial favourable microbiological outcome was noted in 12 cases. Post-treatment cultures in two cases were positive for tigecycline-resistant organisms. CONCLUSIONS: The clinical efficacy of tigecycline for treatment of UTIs has not been extensively evaluated. Based on the available literature, tigecycline appears to have efficacy in some patients with MDR Gram-negative bacillus UTIs. Further research in this area is needed to fully elucidate the role of tigecycline in treating such patients.
Authors: Ga Eun Park; Cheol-In Kang; Yu Mi Wi; Jae-Hoon Ko; Woo Joo Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song Journal: Antimicrob Agents Chemother Date: 2015-06-22 Impact factor: 5.191
Authors: Federico Perez; Nadim G El Chakhtoura; Krisztina M Papp-Wallace; Brigid M Wilson; Robert A Bonomo Journal: Expert Opin Pharmacother Date: 2016-03-09 Impact factor: 3.889
Authors: S M S Ng; J S P Sioson; J M Yap; F M Ng; H S V Ching; J W P Teo; R Jureen; J Hill; C S B Chia Journal: Eur J Clin Microbiol Infect Dis Date: 2017-10-10 Impact factor: 3.267
Authors: Julio Cesar Garcia Casallas; H Robayo-Amortegui; Z Corredor-Rozo; A M Carrasco-Márquez; Javier Escobar-Perez Journal: J Med Case Rep Date: 2019-05-08